Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Catholic University of the Sacred Heart
This study aims to investigate the therapeutic efficacy of PIPAC using cisplatin and doxorubicin in women with first recurrent resistance ovarian cancer and disease progression with peritoneal carcinomatosis. The primary objective of this study is to determine the Clinical Benefit Rate (CBR) according to RECIST/GCOG criteria after three cycles of PIPAC with PIPAC cisplatin and doxorubicin
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients affected by first or second platinum resistant epithelial ovarian tumor recurrence.
ECOG-performance status ≤ 3.
Adequate respiratory, hepatic, cardiac, kidney and bone marrow function (absolute neutrophil count \> 1500 / mm3, platelets \> 150 000/μl, creatinine clearance \> 60 mL / min according to Cockroft formula).
Patient-compliant and psychologically able to follow the trial procedures.
You may not be if
Non-epithelial ovarian cancer or borderline ovarian tumor.
Pregnancy or breastfeeding.
Patients affected by major depressive disorder even in treatment or minor mood disorders.
Patients with severe impairment of respiratory, hepatic or renal function.
Patients with cardiac, neurological or metabolic uncontrolled pharmacologically disease
Patients with bowel obstruction.
Inadequate bone marrow, liver, kidney function.
No clear-peritoneal disease at surgical exploration.
Patients with ascites \>2000 cc (CT-Scan)
Patients who have already made third line chemotherapy.
